AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’

Contributed by: Business Wire

Logo

Tags

Science

Radiology

Biotechnology

Research

Pharmaceutical

Oncology

Health

Clinical Trials

MRFF

More Like This

AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

PR Newswire associated0

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

PR Newswire associated0

IONETIX Corporation and AlfaRim Medical B.V. announce a strategic partnership to fast-track commercial production of Actinium-225

PR Newswire associated0

AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program

PR Newswire associated0

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors